Literature DB >> 17553596

Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistula.

Gregory S Harris1, Robert M Lust, Laxmansa C Katwa.   

Abstract

Urotensin II (UTII) is a potent vasoactive peptide. Recent studies have demonstrated increased expression of both UTII and its receptor (UTR) expression in end-stage congestive heart failure (CHF), but it is unclear whether UTII and UTR are late stage markers of decompensation, or earlier adaptive responses. The purpose of this study was to measure the effects of chronic UTII administration in normal and volume overloaded animals. Chronic 4 weeks administration of UTII produced decreases in hemodynamic function in animals not subjected to volume overload while returning function to control levels in animals with overload. Expression levels of calcium regulatory proteins phospholamban (PLN), sarcoplasmic reticulum Ca(2+) ATPase (SERCA2), and Na(+)/Ca(2+) exchanger (NCX) were measured to determine if administration of UTII resulted in aberrant Ca(2+) handling. Changes in protein expression revealed that UTII influenced Ca(2+) handling proteins in normal animals although these changes are not seen in the volume overload.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17553596      PMCID: PMC2965601          DOI: 10.1016/j.peptides.2007.04.018

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  30 in total

Review 1.  Cardiovascular actions of human urotensin II--considerations for hypertension.

Authors:  Fraser D Russell; Peter Molenaar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-19       Impact factor: 3.000

2.  Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers.

Authors:  D Gruson; M F Rousseau; S A Ahn; F van Linden; J M Ketelslegers
Journal:  Peptides       Date:  2005-12-20       Impact factor: 3.750

3.  Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure.

Authors:  Fraser D Russell; Deborah Meyers; Andrew J Galbraith; Nick Bett; Istvan Toth; Philip Kearns; Peter Molenaar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-06-05       Impact factor: 4.733

4.  Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat.

Authors:  Xi Wang; Bin Ren; Songyan Liu; Emmanuelle Sentex; Paramjit S Tappia; Naranjan S Dhalla
Journal:  J Appl Physiol (1985)       Date:  2003-02

5.  Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure.

Authors:  Melissa Lim; Suzy Honisett; Christopher D Sparkes; Paul Komesaroff; Andrew Kompa; Henry Krum
Journal:  Circulation       Date:  2004-03-08       Impact factor: 29.690

6.  Congestive heart failure and expression of myocardial urotensin II.

Authors:  Stephen A Douglas; Lara Tayara; Eliot H Ohlstein; Nadine Halawa; Adel Giaid
Journal:  Lancet       Date:  2002-06-08       Impact factor: 79.321

7.  Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy.

Authors:  Harald Lapp; Guido Boerrigter; Lisa C Costello-Boerrigter; Karsten Jaekel; Thomas Scheffold; Ingo Krakau; Matthias Schramm; Hartmut Guelker; Johannes-Peter Stasch
Journal:  Int J Cardiol       Date:  2004-03       Impact factor: 4.164

8.  Changes in myosin heavy chain and its localization in rat heart in association with hypobaric hypoxia-induced pulmonary hypertension.

Authors:  Kuniaki Nakanishi; Yasuko Nakata; Fumiko Kanazawa; Shin-Ichiro Imamura; Rumiko Matsuoka; Hiroshi Osada; Toshiaki Kawai; Maki Uenoyama; Takashi Aurues; Tomosumi Ikeda
Journal:  J Pathol       Date:  2002-07       Impact factor: 7.996

9.  Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart.

Authors:  Fraser D Russell; Peter Molenaar
Journal:  Cardiovasc Res       Date:  2004-09-01       Impact factor: 10.787

10.  Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta.

Authors:  Nicolas Bousette; Lisa Patel; Stephen A Douglas; Eliot H Ohlstein; Adel Giaid
Journal:  Atherosclerosis       Date:  2004-09       Impact factor: 5.162

View more
  2 in total

1.  Urotensin II alters vascular reactivity in animals subjected to volume overload.

Authors:  Gregory S Harris; Robert M Lust; Laxmansa C Katwa; Christopher J Wingard
Journal:  Peptides       Date:  2010-08-17       Impact factor: 3.750

2.  PPAR-gamma expression in animals subjected to volume overload and chronic Urotensin II administration.

Authors:  Gregory S Harris; Robert M Lust; Jonathan H DeAntonio; Laxmansa C Katwa
Journal:  Peptides       Date:  2008-03-12       Impact factor: 3.750

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.